Radiance Receives CE Mark for the RDXTM Coronary ... - Endologix

page 2Radiance is currently conducting the BRITE II Study in the United States forthe treatment of instent restenosis. Enrollment in this trial began in January 2001 andis scheduled to complete enrollment later this year.Radiance Medical Systems, Inc. develops radiation delivery catheters intendedfor use in the cardiovascular or coronary and peripheral vascular systems to preventrestenosis following the interventional treatment of atherosclerosis. In addition,Radiance markets coronary stents, coronary stent delivery systems and balloondilatation catheters for coronary applications. For more information about Radiance,visit the Company’s website at: www.Radiance.net.Except for historical information contained herein, this news release contains forward-lookingstatements, the accuracy of which are necessarily subject to risks and uncertainties. Actual results may beaffected by, among other things, risks and uncertainties related to new product development andintroduction cycles, research and development activities, including failure to demonstrate clinicalefficacy, delays by regulatory authorities, scientific and technical advances by third parties, introductionof competitive products, third party reimbursement and physician training, and other risk factors andmatters set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2000and the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2001.# # #